

Please cancel the present "SEQUENCE LISTING", submitted on compact disc in accordance with 37 C.F.R. §1.821(c), and insert therefor the accompanying Substitute Sequence Listing submitted on compact disc in accordance with 37 C.F.R. §1.821(c).

REMARKS

Please replace the two copies of the written Sequence Listing, submitted on compact disc in accordance with 37 C.F.R. §1.821(c) filed November 21, 2000, with the two substitute copies of the written Sequence Listing submitted herewith on compact disc in accordance with 37 C.F.R. §1.821(c). The required duplicate copies of the written form on compact disc are labeled "Copy 1 of 3" and "Copy 2 of 3". The computer readable form of the Substitute Sequence Listing is also submitted on compact disc, labeled "Copy 3 of 3".

Each compact disc is formatted for IBM-PC, MS-Windows 98. Each disc contains one file: -141.APP, 2,440,535 bytes, created on April 26, 2001 containing the above named sequences, SEQ ID NOS:1-14528. The duplicate copies of the written form on compact disc and the computer readable form of the Substitute Sequence Listing on compact disc are identical, *i.e.*, "Copy 1 of 3" and "Copy 2 of 3" of the compact discs are identical, and the sequence information recorded in computer readable form on compact disc, *i.e.*, "Copy 3 of 3", is identical to the written (on compact disc) Substitute Sequence Listing.

In order to expedite prosecution, Applicants have included the theoretical peptides (SEQ ID NOS:14527 and 14528) in the Substitute Sequence Listing as requested by the Examiner. Applicants note that each amino acid position TABLE III independently defines preferred and deleterious residues; there is no basis in the specification to assume otherwise. Thus, a peptide with a preferred residue at position 3, for example, need not have another preferred residue at position 4. The Examiner's request to include a specific sequence for the amino acid residues set forth at positions 1-9 for DR7 from TABLE III, page 97, in the Substitute Sequence Listing is therefore directed to a purely theoretical peptide that would comprise all of the preferred residues (SEQ ID NO:14527) or all of the deleterious residues (SEQ ID NO:14528) at secondary positions. These amendments to the specification add no new matter.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,



Matthew E. Hinsch
Reg. No. 47,651

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: (415) 576-0200
Fax: (415) 576-0300
MEH:dmw

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Specification:

Paragraph beginning at line 35 of page 1 has been amended as follows:

The Sequence Listing written in file -141.APP ~~141ultra.txt~~, 2,440,535 ~~2,439,302~~ bytes, created on April 26, 2001 ~~November 21, 2000~~ on two identical copies of compact discs for Application No: 09/412,863, Sette *et al.*, Inducing Cellular Immune Responses To Human Immunodeficiency Virus-1 Using Peptide And Nucleic Acid Compositions, is hereby incorporated by reference.

Paragraph beginning at line 1 of page 97 (TABLE III) has been amended as follows:

TABLE III

POSITION

| <u>MOTIFS</u> | <u>1° anchor 1</u> | <u>2</u> | <u>3</u> | <u>4</u> | <u>5</u> | <u>1° anchor 6</u> | <u>7</u> | <u>8</u> | <u>9</u> |
|------------------------------|--------------------|----------|----------|--------------------|----------|--------------------|----------|-----------|-----------|
| DR4 preferred deleterious | FMYLIVW | M | T | | I | VSTCPALIM | MH R | MH WDE | MH WDE |
| DR1 preferred deleterious | MFLIVWY | | | PAMQ FD | CWD | VMATSPLIC | M GDE | | AVM |
| DR7 preferred deleterious | MFLIVWY | M C | W | A G | | IVMSACTPL | M GRD | | IV G |
| DR Supermotif | MFLIVWY | | | | | VMSTACPLI | | | |
| <u>DR3 MOTIFS</u> | <u>1° anchor 1</u> | <u>2</u> | <u>3</u> | <u>1° anchor 4</u> | <u>5</u> | <u>1° anchor 6</u> | | | |
| motif a preferred | LIVMFY | | | D | | | | | |
| motif b preferred | LIVMFAY | | | DNQEST | | KRH | | | |

Italicized residues indicate less preferred or "tolerated" residues.